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Abstract: Nowadays, obesity and its associated metabolic disorders, including diabetes, metabolic
syndrome, cardiovascular disease, or cancer, continue to be a health epidemic in westernized societies,
and there is an increased necessity to explore anti-obesity therapies including pharmaceutical
and nutraceutical compounds. Considerable attention has been placed on the identification of
bioactive compounds from natural sources to manage the metabolic stress associated with obesity.
In a previous work, we have demonstrated that a CO2 supercritical fluid extract from yarrow
(Yarrow SFE), downregulates the expression of the lipogenic master regulator SREBF1 and its
downstream molecular targets FASN and SCD in a tumoral context. Since obesity and diabetes
are strongly considered high-risk factors for cancer development, herein, we aimed to investigate
the potential therapeutic role of Yarrow SFE in the metabolic stress induced after a high-fat diet in
mice. For this purpose, 32 C57BL/6 mice were distributed in four groups according to their diets:
standard diet (SD); SD supplemented with Yarrow SFE (SD + Yarrow); high-fat diet (HFD); and HFD
supplemented with Yarrow SFE (HFD + Yarrow). Fasting glycemia, insulin levels, homeostasis model
assessment for insulin resistance (HOMA-IR), lipid profile, gene expression, and lipid content of
liver and adipose tissues were analyzed after three months of treatment. Results indicate improved
fasting glucose levels in plasma, enhanced insulin sensitivity, and diminished hypercholesterolemia
in the HFD + Yarrow group compared to the HFD group. Mechanistically, Yarrow SFE protects liver
from steatosis after the HFD challenge by augmenting the adipose tissue buffering capacity of the
circulating plasma glucose.
Keywords: yarrow supercritical extract; obesity; diabetes; insulin resistance; hypercholesterolemia;
fatty liver; cancer
1. Introduction
According to the World Health Organization (WHO), in 2016, more than 650 million people
were estimated as obese. The prevalence of obesity and its associated metabolic disorders, including
diabetes, metabolic syndrome, cardiovascular disease, and cancer is rapidly becoming a severe global
health problem [1,2].
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In the course of obesity, the increased lipid accumulation induces a systemic chronic inflammation
that promotes an abnormal cellular response to insulin, leading to insulin resistance and type 2 diabetes
(T2D). In this regard, the International Federation Atlas (2018) has estimated over 415 million people
diagnosed with diabetes, with 90% of the cases being Type 2 diabetes (T2D) [3–5]. Whether insulin
resistance triggers hyperinsulinemia or hyperinsulinemia, in turn, causes insulin resistance is still
under debate [6].
Obesity and type 2 diabetes (T2D) not only are considered risk factors for the appearance of
multiple types of cancers (liver, breast, colon, pancreatic, esophageal, among others), but also correlate
with poorer prognosis [2–8]. WHO has estimated that one-third of cancers could be prevented by
modifying risk factors, such as augmenting physical activity and reducing the intake of saturated fatty
acids or high-glucose-containing drinks.
Current therapeutic strategies for attenuating obesity and insulin resistance include lifestyle
modifications (e.g., diet, exercise, weight loss) prior to the administration of pharmacological agents
(e.g., insulin-sensitizing drugs), which are prescribed only for patients with a body mass index
(BMI) ≥27 kg/m2. Bariatric surgery is considered only for patients with a BMI of 30–40 kg/m2 [9,10].
Due to the complications of insulin-sensitizer drugs, alternative remedies in the form of dietary agents
to attenuate insulin resistance are receiving more interest.
In this regard, phytochemicals from natural sources are drawing attention, as therapeutic or
preventing agents to manage alterations associated with chronic diseases related to metabolism [11,12].
Some of them have been shown to reduce adipose tissue mass, to decrease metabolic stress, to mimic
the action of insulin and/or to act as potent anti-hyperglycemic agents [13–15].
In a previous work, we have demonstrated that Yarrow (Achillea millefolium) supercritical fluid
extract (Yarrow SFE) downregulates the expression of the lipogenic genes SREBF1, FASN, and SCD1
in a pancreatic cancer model [16]. Herein, with obesity and diabetes being considered risk factors
in cancer [17], we aimed to investigate whether Yarrow SFE could restore the lipid and/or glucose
homeostasis after a high-fat diet induced obesity.
Our results indicate Yarrow SFE improves circulating fasting glucose levels, enhances insulin
sensitivity, and diminishes hypertriglyceridemia and hypercholesterolemia. Mechanistically, Yarrow
SFE protects liver from steatosis after the high-fat diet (HFD) challenge by augmenting the adipose
tissue buffering capacity of the circulating plasma glucose. In conclusion, Yarrow SFE could be
proposed as a nutritional supplement in obesity and diabetes therapy.
2. Materials and Methods
2.1. Yarrow Supercritical Fluid Extract (SFE)
Yarrow SFE extract was obtained with supercritical CO2 using the extractor Thar Technology
model SF2000 (Pittsburgh, PA, USA), with a 2 L extraction cylinder and two 0.5 L separators. Pressure
(±0.1 MPa) and temperature (±2 K) were controlled independently.
Ground Yarrow was subjected to 40 ◦C and 140 Bar with a CO2 flux of 70 g/min during 180 min.
The composition and chemical characterization of this extract has been described previously [18].
2.2. Animals and Treatment
In this study, C57BL/6 mice were housed in a temperature- and humidity-controlled room with
a cycle of 12 h light/darkness allowing free access to water and food. A total of 32 mice were randomly
distributed in two groups according to their diets (values are referenced to the percentage of the
energy they contribute—Kcal/kg): standard chow diet (SD) group (proteins 18.2%, carbohydrates
73.1%, and fat 8.6%; D40 -Rats, Mice Maintenance Diet-RMM, Safe) and high-fat diet group (HFD)
(proteins 20%, carbohydrates 35%, and fats 45%; D12451 Research Diets, Inc., New Brunswick, NJ, USA).
After three months with the SD or the HFD, animals of each group were randomly distributed in two
additional groups for the intervention period (in the presence or absence of Yarrow SFE, 800 mg/Kg
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Yarrow five times per week) during three months ending up with four groups: SD; SD + Yarrow;
HFD; and HFD + Yarrow. The dose was chosen based on a previous study to determine the putative
toxicity of the extract in acute. Different doses ranging from 200 to 1000 mg/Kg of Yarrow SFE were
administered to mice by gavage. No effects were observed on markers regardless of renal or liver
dysfunctions or the animal’s general health or behavior.
All procedures of the study were approved by the Research and Animal Welfare Ethics Committee
of the Consejo Superior de Investigaciones Cientificas (CSIC) and the Environment Counseling of
Community of Madrid (PROEX112/17), under the provisions of RD53/2013 law. The experiments were
performed in the animal facilities of the Center for Biological Research (CIB-CSIC).
Animals were anesthetized with isoflurane 4–5%, followed by a cardiac puncture, in order to
collect the maximum volume of blood.
2.3. Glucose Tolerance Test and Insulin Level Measurement
Glucose tolerance tests (GTT) were performed on mice fasted for 18 h. In all cases, 2 g/kg of
glucose (Sigma) was intraperitoneally injected. Blood glucose levels were measured in fasted animals
at 15, 30, 60, and 120 min after the glucose injection by mean of the Glucomen blood glucose monitoring
system (A. Menarini Diagnostics).
Insulin levels in fasted animals were measured with the Ultrasensitive Mouse Insulin ELISA
(enzyme linked immunosorbent assay) kit (#90080 Crystal Chem.).
The HOMA-IR index (homeostasis model Assessment for insulin resistance) was calculated with the
formula (insulin × glucose/22.5), where insulin and glucose are the fasting insulin and glucose levels [19].
For GTT and insulin tolerance test (ITT) analysis, blood was obtained after a superficial cut at the
end of the tails. For insulin determinations, the same protocol was used but with tubes designed to be
filled by capillarity, which allowed to obtain up to 20 µL.
2.4. Biochemical Analysis
Body weight was monitored twice a week and food intake once per week.
The entire blood, obtained by the cardiac puncture at the end of the study, was used to determine
the levels of the (i) hepatic ALT (alanine transaminase) and AST (aspartate transaminase) enzymes,
(ii) the lipid profile (total cholesterol, HDL-cholesterol, LDL-cholesterol, NEFA (non-esterified fatty
acids), and (iii) the urea levels.
All the biochemical determinations were carried out at the Center for Applied Medical Research
of Navarra. Serum levels of cholesterol, ALT, AST, urea, and NEFAs were determined using a Cobas
C311 Autoanalyzer (Roche, Basel, Switzerland) by routine laboratory methods from Roche or, in the
case of NEFAs, from Wako (Wako Chemicals Europe, Neuss, Germany).
2.5. RT-PCR and Real-Time PCR
Liver and adipose tissues obtained from the sacrificed animals at the end of the study,
were immediately frozen. RNA extraction from tissues was performed in dried ice to minimize RNA
degradation. Samples were cut and quickly introduced in Trizol (Qiagen, Madrid, Spain) followed by
a homogenization with the Ultra-Turrax (T10, IKA, Breisgau, Germany). RNA was extracted using the
miRNeasy Mini Kit (Qiagen, Hilden, Germany), which combines cell lysis with a silica membrane-based
purification. Total RNA was quantified with UV–vis spectrophotometer (NanoDrop 2000/2000c,
ThermoFisher, Madrid, Spain). Reverse transcription was performed with the High-Capacity cDNA
Reverse Transcription kit (ThermoFisher, Madrid, Spain), following manufacturer’s instructions.
RT-PCR reactions were performed in 20 µL at 25 ◦C 10 min, 37 ◦C 120 min, and 85 ◦C 5 min.
The 7900HT Fast Real-Time q-PCR (Applied Biosystems, Waltham, MA, USA) was done using the same
amount of cDNA of each tissue, with specific probes (Taqman): SREBF1 (Mm00550338_m1); FASN
(Mm00662319_m1), SCD (Mm00772290_m1), GLUT4 (Mm00436615_m1), IRS1 (Mm01278327_m1),
and two endogenous house-keeping genes: 18S (Mm03928990_ g1) and GAPDH (Mm99999915_g1).
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Gene expression analysis was carried out with the software RQ Manager (ThermoFisher, Madrid, Spain),
and the relative expression (RQ) of each gene was determined following the 2−∆∆Ct method (Livak) [20].
2.6. 1H NMR Analysis of the Lipid Content in Liver and Adipose Tissues, and Glycogen and Choline Content
in Liver Tissues
High Resolution Magic Angle Spinning (HR MAS) spectra were acquired from an 11.7 Tesla Bruker
Avance spectrometer operating at 500.113 MHz, at 4 ◦C and 5 KHz spinning rate. 1D 1H HR MAS spectra
were acquired using Carr–Purcell–Meiboom–Gill (CPMG) sequence with 2 s water pre-saturation,
144 ms echo time, and 128 scans. Data were collected into a 32 K data point using a spectral width of
10 KH (20 ppm) and water pre-saturation during a relaxation delay of 2 s and 1D sequence for the
diffusion measurement using stimulated echo with bipolar gradient pulses (stebpgp1s1d) with big
delta 200 ms and little delta 1.2 ms. A sine-shaped gradient was followed by a 300 µs delay for gradient
recovery, 5 kHz spectral width, 32 K data point, and 128 scans. Quantification of detectable metabolites
in the ex vivo spectra was performed by measuring the area of the peaks using the MestReC software
(Mestrelab Research, Santiago de Compostela, Spain). Data were manually phased and baseline
corrected. NMR spectra were referenced to the FA terminal –CH3 signal at δ 0.89 ppm. The analysis of
the metabolites was performed by selecting the following resonances:
· Methyl groups (–CH3) at 0.89 ppm (saturated fatty acid chains)
· –CH3 at 0.96 ppm (n-3 EPA and DHA)
· Acyl chains methylenes ((CH2)n at 1.33 ppm
· CH2–C–CO at 1.58 ppm
· CH2C=C at 2.02 ppm
· CH2CO other than DHA at 2.25 ppm
· CH2CO of DHA at 2.33 ppm
· =C–CH2–C= at 2.78 ppm
· –CH=CH– at 5.33 ppm
· Choline at 3.2 ppm
· Phosphocholine at 3.19 ppm
· Glycogen at 5.3 ppm
2.7. Statistical Analysis
Results are shown as means ± the standard error of the mean (SEM). Statistical analyses were
performed using GraphPad (v.7.03 Software, Inc., San Diego, CA, USA). The comparison between the
groups was performed by one-way ANOVA followed by Bonferroni’s post-test. Statistical differences
were considered as follows: * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p < 0.0001.
3. Results
3.1. Study Workflow
As Yarrow SFE diminishes the expression of SREBF1 in pancreatic cancer cells and in a xenograph
mouse model [16], we wanted to analyze the impact of Yarrow SFE in C57/Bl6 mice under standard
diet (SD) or high-fat diet (HFD)-induced obesity.
Two different glucose and insulin tolerance tests were performed: (1) after three months of
intervention with SD or HFD, in the absence of Yarrow, and (2) after three additional months in which
the SD or HFD was combined or not with Yarrow (final end point of the experiment was six months).
The time elapsed between the end of the second test and the sacrifice of animals was one week to
allow animals to recover from the GTT/ITT intervention.
Figure 1 shows the study workflow together with the biochemical and molecular determinations.
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Figure 1. Study workflow together with the main biochemical and molecular determinations. SD—standard
diet; HFD—high-fat diet; GTT—glucose tolerance test; ITT—insulin tolerance test—ALT—alanine
transaminase; AST—aspartate transaminase.
3.2. Yarrow SFE Diminishes Plasma Glucose Levels in a Pre-Diabetic Model Induced by HFD
After three months of SD or HFD, a glucose tolerance test (GTT) was performed to confirm the
pre-diabetic state in the HFD group compared to SD group.
As shown in Figure 2A, mice exposed to HFD, displayed statistically significant higher circulating
glucose levels compared to the SD group. These results indicate hyperglycemia and a pre-diabetic state in the
HFD group.
At this point, the intervention period—absence/presence of Yarrow for three additional
months—was initiated, and after this a second GTT analysis was performed. There were not
found statistically significant differences between the SD and the SD + Yarrow groups, indicating
that yarrow had no impact on the circulating glucose levels under SD. As expected, the HFD group
displayed increased circulating levels of glucose compared to the SD group. Importantly, only the
HFD + Yarrow group restored the levels of circulating glucose to that of the SD group after 60 min of
the glucose injection (Figure 2B). These results indicated that Yarrow SFE was able to ameliorate, to
some extent, the glucose levels in the obese and hyperglycemic animals.
Figure 2. (A) GTT test and area under the curve (AUC) comparisons between SD and HFD groups
showing statistically significant differences between the SD and HFD groups (pre-diabetic state).
(B) GTT test and the AUC comparisons between SD ± Yarrow and HFD ± Yarrow after the three
additional months of the intervention period (yarrow treatment was 800 mg/kg). Values are means ±
SEM of 6–8 mice per condition. ** p < 0.01; *** p < 0.001; **** p < 0.00001.
3.3. Yarrow SFE Improves Insulin Sensitivity in a Pre-Diabetic Model Induced by HFD
To study the impact of Yarrow SFE in the sensitivity to insulin, basal insulin levels were quantified
in the four groups after 18 h of fasting. As expected, HFD displayed statistically significant increased
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insulin levels compared to the control SD group. Importantly, insulin levels in the HFD + Yarrow
group was not statistically different from that of the SD group (Figure 3A).
Moreover, calculated HOMA-IR index, which estimates the resistance to insulin, showed higher index
in the HFD group compared to the HDF + Yarrow group (Figure 3B). Thus, animals treated with yarrow,
although still considered as insulin resistant (IR > 3), displayed an improved sensitivity to insulin.
Figure 3. Insulin levels (A) and homeostasis model assessment for insulin resistance (HOMA–IR) (B)
after three months of the intervention period ± Yarrow (800 mg/kg). Values are expressed as means ±
SEM, 6–8 mice per condition. Asterisks indicate differences related to the SD group. *** p < 0.001.
The food intake was monitored (once per week) and so was the body weight (twice per week).
No significant differences were found in the amount of food intake compared to SD group (Figure S1).
Regardless of body weight, no significant differences were found between the HFD + Yarrow and HFD
groups, nor between the SD + Yarrow and the SD groups in our experimental conditions (Figure S2).
3.4. Yarrow SFE Decreases Total Plasma Cholesterol Levels and NEFA Levels after HFD-Induced Obesity
As obesity is frequently associated with increased circulating plasma levels of NEFA and cholesterol,
we wanted to evaluate the impact of Yarrow SFE on these parameters. As shown in Figure 4, NEFA
diminished in the HFD + Yarrow group compared to the HFD group. Similarly, total cholesterol levels
were improved in the HFD + Yarrow group compared to the HFD group, although without recovering
to the levels of the SD groups. In addition, the ratio LDL-C/HDL-C was also improved in the HFD +
Yarrow group compared to the HFD group.
Figure 4. Lipid prolife of SD and HFD mice treated or not with Yarrow SFE (supercritical fluid extract).
Values represent the mean ± SEM of 6–8 mice per condition. Statistical differences relative to the SD
group are indicated as * p < 0.05; *** p < 0.001 and **** p < 0.0001. Statistical differences found between
HFD and HFD Yarrow groups are indicated as ### p < 0.001 and #### p < 0.0001.
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3.5. Yarrow SFE Is Well Tolerated and Diminishes Biomarkers of Hepatic Damage
To discard any toxicity associated with the administration of Yarrow SFE after a prolonged
administration (three months of intervention period), biomarkers of the hepatic and renal functions
were analyzed: ALT, AST, and urea levels. As shown in Figure 5, AST and ALT levels were found
increased in the HFD group compared to the SD group. Importantly, ALT circulating levels were
statistically diminished in the HFD + Yarrow group compared to the HFD group. The AST circulating
levels displayed a tendency to diminish, although without reaching the levels of the control SD group.
Regarding the urea levels, all groups behaved similarly. These results indicated that Yarrow SFE was
well tolerated.
Figure 5. Analysis of circulating hepatic and renal parameters (ALT, AST, Urea) of obese and normal
mice treated with 800 mg/kg Yarrow SFE extract and their controls. Values represent the mean ± SEM
of 6–8 mice per condition. * Indicates differences compared to the SD group; and # to the HFD group.
* p < 0.05; ** p < 0.01.
3.6. Yarrow SFE Reduces De Novo Lipogenesis and the Fatty Acid Content in Livers after
HFD-Induced Obesity
To study the effect of Yarrow on the hepatic de novo lipogenesis, we first quantified the expression
levels of the master lipogenic transcription factor SREBF1, and its downstream molecular targets FASN
and SCD1. As shown in Figure 6A, the HFD + Yarrow group displayed a statistically significant
reduction in the expression levels of FASN and SCD1 compared to the HFD group.
As the liver is a crucial organ for the maintenance of the systemic glucose homeostasis, we also
analyzed the expression levels of the glucose transporter (GLUT4) and the insulin receptor substrate 1
(IRS1), a downstream regulator of the insulin signaling. As shown in Figure 6A, the GLUT4 and IRS1
expression levels were diminished in the HFD + Yarrow group compared to the HFD group, although
without restoring the levels to that of the SD animals (not shown). These results indicate that livers
from the HFD + Yarrow group had a diminished insulin signaling compared to the HFD group which,
together with the improved HOMA-IR, reinforces a role of Yarrow SFE in alleviating insulin resistance.
By means of NMR analysis, we quantified the relative fatty acid content and choline and glycogen
levels of livers from the HFD + Yarrow and the HFD groups (10 mg of tissue analyzed). As shown
in Figure 6B, the relative comparison of the fatty acid liver contents showed a tendency to diminish
in the HFD + Yarrow group, although not statistically significant. Importantly, the relative choline
levels (choline and phosphate choline) were statistically improved in livers from mice in the HFD +
Yarrow group compared to the HFD group (Figure 6C). Regardless of glycogen content no statistically
significant differences were found between HFD + Yarrow and HFD (Figure 6D).
In summary, all these results suggest a better performance of livers from the HFD + Yarrow group
compared to those from the HFD group.
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Figure 6. (A) Gene expression of SREBF1, FASN, SCD1, GLUT4, and IRS1 genes in livers from HFD
+ Yarrow and HFD groups. (B) Quantification of the relative fatty acid content. (C) Choline and
(D) glycogen contents of the livers from HFD + Yarrow and HFD groups (NMR analysis of 10 mg of
tissues). Data represent the mean ± SEM of 6–8 mice per condition. * p < 0.05.
3.7. Yarrow SFE Increases the Uptake of Glucose in the Adipose Tissue but Not the Adipose Tissue Fatty
Acid Content
Adipose tissue (AT), which is insulin-sensitive, is considered a key regulator of the systemic metabolism
and its deregulation encompasses insulin resistance, dyslipidemia, and/or glucose intolerance [21,22].
In a non-obese situation, after feeding, insulin inhibits the AT lipolysis promoting lipogenesis.
On the contrary, during fasting or exercising, lipolysis is induced. In this way, AT acts as an energy
buffer to store the excess of energy and to prevent harmful effects of FFA elsewhere in the body.
Nevertheless, during insulin resistance, AT can promote the ectopic deposition of fatty acids or
lipotoxicity in other tissues.
As Yarrow SFE improved the insulin sensitivity and the plasma lipid profile, we wanted to know
whether Yarrow SFE could affect the glucose uptake (GLUT4, IRS1) and the TG storage capacity
(SREBF1, FASN, SCD1) of the AT after the HFD challenge.
As observed in Figure 7A, the HFD + Yarrow group significantly increased the expression levels
of FASN, SCD1, Glut4, and IRS1 compared to the HFD group. These results suggest an improved
insulin sensitivity of the AT favoring the uptake of circulating glucose to be redirected toward the
synthesis of FAs with more control of unsaturated FAs (Figure 7B). Importantly, the expression levels
of SREBF1 were not augmented, and the relative comparison of the fatty acid content was similar to
the HFD + Yarrow group (NMR analysis). This, together with the reduced circulating levels of FFA,
suggests that Yarrow improves the systemic metabolic stress after the HFD challenge.
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Figure 7. (A) Gene expression of the lipogenic SREBF1, FASN, and SCD1 genes and Glut4 and IRS1
genes of epididymal adipose tissues from HFD + Yarrow and HFD groups. (B) Quantification of
relative fatty acid content of epididymal adipose tissues from HFD + Yarrow and HFD groups (NMR
analysis comparison from 10 mg of tissue). Data represent the mean ± SEM of 6–8 mice per condition. *
p < 0.05, ** p ≤ 0.01.
4. Discussion
The main objective of the present work was to assess the potential benefit of Yarrow SFE extract in
a model of high-fat diet induced obesity. For this purpose, and as indicated in the study workflow
(Figure 1), 32 mice were distributed in two groups. After three months of SD (n = 16) or HFD (n = 16),
the GTT analysis indicated a pre-diabetic status in the HFD group. The subsequent three months of
the intervention period (presence or absence of Yarrow SFE) showed that Yarrow SFE was able to
ameliorate the hyperglycemia compared to the HFD group. No differences were found between mice
in the SD ± Yarrow groups (Figure 2).
In addition, insulin levels were improved in the HFD + Yarrow group compared to the HFD
group (Figure 3).
Yarrow SFE was able to alleviate to some extent the lipid profile in plasma and the hepatic
lipid accumulation when compared to the HFD group (Figure 4). Moreover, Yarrow SFE diminished
biomarkers of hepatic damage in the HFD + Yarrow group compared to the HFD group (Figure 6).
Different mechanisms seem to be responsible for these effects.
Insulin is a key regulator of many processes. In normal conditions, in the adipose tissue, insulin
promotes glucose to be re-directed toward de novo lipogenesis and triglyceride storage. On the
other hand, in the liver, insulin stimulates the synthesis of glycogen and diminishes the hepatic
gluconeogenesis, preventing the efflux of glucose into the bloodstream. Nevertheless, during obesity
and diabetes, insulin resistance is manifested by increased lipolysis from adipose tissue and increased
de novo lipogenesis and gluconeogenesis in the liver [23–25].
In this study, Yarrow SFE influences the glucose and lipid homeostasis between liver and adipose
tissues. Livers from the HFD + Yarrow group displayed a significant decrease in the expression
levels of FASN compared to the HFD group. Moreover, the decreased in the expression levels of IRS1
suggests a decreased intracellular insulin signaling in livers from the HFD + Yarrow group. This is
in accordance with the NMR quantification of the fatty acid liver content, which showed a tendency
toward a reduction of the total fatty acid content. It would have been interesting to determine the
intrahepatic cholesterol levels, although the improvement in the choline levels suggests a better
performance of livers from the HFD + Yarrow group compared to the HFD group.
During obesity and insulin resistance, the adipose tissue presents (i) a diminished ability to capture
glucose due to the downregulation of GLUT4, the major insulin-regulated glucose transporter [26,27],
and (ii) an increased lipolysis and release of fatty acids and glycerol [28,29], shifting down the
lipogenic process.
Adipose tissue has developed adaptive mechanisms to cope with the metabolic stress during
obesity. Herein, we found that although the expression levels of SREBF1 were kept similar, FASN
and SCD1 expression levels were increased in the HFD + Yarrow group compared to the HFD
group. Importantly, Yarrow SFE increased the expression levels of the glucose transporter GLUT4.
This, together with the increased FASN and SCD1 expression levels in the adipose tissue, suggests
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an increased capability of adipose tissues from HFD + Yarrow group to redirect the circulating glucose
toward the synthesis of fatty acids and triglycerides. The increase in GLUT4 may also partially explain
the diminished hyperglycemia found in the HFD + Yarrow group compared to the HFD group.
There is controversy regarding whether the increase of FASN and SCD1 in the adipose tissue of
obese individuals is or is not an SREBP1-dependent process [30]. In the last years, many results support
the idea that SREBF1 is not responsible of the increased lipogenesis in the adipose tissue [31] due to
the activation of FASN and SCD1 regulated by the intracellular glucose levels. The regulatory feedback
control point of the Insig1/SREBP1 axis allows to compensate the anti-lipogenic effects associated
with insulin resistance by augmenting the FASN and SCD1 expression levels without augmenting the
expression levels of SREBF1, although regulating the protein levels of the mature SREBP1 transcription
factor [32]. Here, SREBF1 expression levels were not increased in the epididymal adipose tissue of the
HFD + Yarrow group compared to the HFD group, suggesting that the increase of FASN and SCD1
may be regulated by the increase glucose uptake. Similar results have been found in vitro in 3T3L1
cells treated with Yarrow SFE (data not shown).
No significant differences were found between body weights of HFD + Yarrow and HFD groups,
nor between SD + Yarrow and SD groups in our experimental conditions. Although in this study the
subcutaneous adipose tissue was not quantified, the observed reduction of FASN and SCD1 in the
livers of the HFD + Yarrow group, together with the reduction of hepatic damage biomarkers, suggests
a healthier distribution of adipose tissue against visceral lipotoxic accumulation.
5. Conclusions
In the course of obesity and insulin resistance, increased lipolysis from adipose tissue is observed.
The excess of TG and NEFA in ectopic tissues such as liver, pancreas, and muscle, disrupts the systemic
metabolic control of lipids and glucose. Insulin resistance in liver, induces gluconeogenesis and de
novo fatty acid synthesis, ending up with increased glucose release and hepatic steatosis [33,34].
Herein, Yarrow SFE improved the plasma glucose levels and ameliorated the insulin resistance in
an HFD model of obesity. Yarrow SFE augmented the adipose tissue buffering capacity of circulating
glucose toward the synthesis of fatty acids and triglycerides. In addition, Yarrow SFE diminished
the expression levels of FASN and SCD1 in livers after an HFD, reducing the overall fatty acid liver
content. Importantly, Yarrow SFE also diminished the expression levels of IRS1 in the livers which
may contribute to decrease the intracellular insulin signaling after an HFD. The increased in the
choline levels suggests a better performance of livers from the HFD + Yarrow group compared to
the HFD group, as high choline levels have been shown to protect against fatty liver disease or even
hepatocarcinoma [35,36]. Linked to this, the HFD + Yarrow group presented a tendency toward
increased levels of glycogen which suggests a better performance for the storage of glucose in the liver
in accordance with the improvement in insulin sensitivity.
Although an ethanolic extract of Yarrow has been described to improve the circulating glucose
levels in a diabetic model [37], herein SFE Yarrow also improved the lipid profile and ameliorated the
hepatic steatosis in an HFD model of obesity. Altogether, our results indicate that Yarrow SFE may be
beneficial for obese and hypercholesterolemic patients.
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Food intake monitoring of SD and SD + Yarrow groups, and HFD and HFD +Yarrow groups. No significant differences
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groups, nor between SD + Yarrow and SD.
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